 Subjects will be randomized 1:1 to treatment with tivozanib or sorafenib and stratified by geographic region North AmericaWestern Europe, CentralEastern Europe, or rest of the world; number of prior treatments 0 or 1; and number of metastatic sitesorgans involved 1 or 2. 